Author: Gao, Feng; Zheng, Kenneth I.; Yan, Hua-Dong; Sun, Qing-Feng; Pan, Ke-Hua; Wang, Ting-Yao; Chen, Yong-Ping; Targher, Giovanni; Byrne, Christopher D.; George, Jacob; Zheng, Ming-Hua
Title: Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019 Cord-id: 5r9q3sou Document date: 2021_3_8
ID: 5r9q3sou
Snippet: BACKGROUND AND AIM: Circulating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to describe the association between circulating IL-6 levels and MAFLD at hospital admission with risk of severe COVID-19. METHODS: A total of 167 patients with laboratory-confirmed COVID-19 from three Chinese
Document: BACKGROUND AND AIM: Circulating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to describe the association between circulating IL-6 levels and MAFLD at hospital admission with risk of severe COVID-19. METHODS: A total of 167 patients with laboratory-confirmed COVID-19 from three Chinese hospitals were enrolled. Circulating levels of IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured at admission. All patients were screened for fatty liver by computed tomography. Forty-six patients were diagnosed as MAFLD. RESULTS: Patients with MAFLD (n = 46) had higher serum IL-6 levels (median 7.1 [interquartile range, 4.3–20.0] vs. 4.8 [2.6–11.6] pg/mL, p = 0.030) compared to their counterparts without MAFLD (n = 121). After adjustment for age and sex, patients with MAFLD had a ~2.6-fold higher risk of having severe COVID-19 than those without MAFLD. After adjustment for age, sex and metabolic co-morbidities, increased serum IL-6 levels remained associated with higher risk of severe COVID-19, especially among infected patients with MAFLD (adjusted-odds ratio 1.14, 95% CI 1.05–1.23; p = 0.002). There was a significant interaction effect between serum IL-6 levels and MAFLD for risk of severe COVID-19 (p for interaction = 0.008). CONCLUSIONS: Patients with MAFLD and elevated serum IL-6 levels at admission are at higher risk for severe illness from COVID-19.
Search related documents:
Co phrase search for related documents- abnormal liver function and liver enzyme: 1, 2, 3, 4, 5, 6
- abnormal liver function and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- abnormal liver function and liver similar: 1
- abnormal liver function and logistic regression: 1, 2, 3
- abnormal liver function and lymphocyte neutrophil: 1
- abnormal liver function and macrophage activation: 1
- absolute number and logistic regression: 1, 2, 3, 4, 5
- absolute number and lymphocyte absolute number: 1, 2, 3, 4, 5, 6, 7
- absolute number and lymphocyte neutrophil: 1, 2, 3, 4
- absolute number and lymphocyte neutrophil ratio: 1, 2
- active cancer and liver cancer: 1
- active cancer and liver enzyme: 1
- active cancer and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- active cancer and lymphocyte neutrophil: 1, 2, 3, 4
- active cancer and lymphocyte neutrophil ratio: 1, 2
Co phrase search for related documents, hyperlinks ordered by date